Tarsus Pharmaceuticals Inc (TARS)
R&D to Revenue
17.83%
Quarterly · Period ending:
TARS R&D to Revenue
Latest reported17.83%period ending
Latest reported17.83%period ending
TARS Quarterly R&D/Revenue (0.00% → 17.83%)
Latest values, visible window
High-resolution chart · PNG
TARS r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 17.8309% | |
| 13.7923% | |
| 11.8911% | |
| 13.719% | |
| 15.1899% | |
| 18.3941% | |
| 25.4081% | |
| 25.2047% | |
| 30.184% | |
| 43.6952% | |
| 101.7513% | |
| 646.9802% | |
| 0% | |
| 494.24% | |
| 100.28% | |
| 0% | |
| 62.8592% | |
| 2,241.3729% | |
| 2,378.1065% | |
| 823.3065% | |
| 32.7202% | |
| 48.639% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |